Oncoheroes Biosciences Inc, CataloniaBio & HealthTech member, and Boehringer Ingelheim International GmbH have signed a worldwide licensing agreement for the anti-cancer compound volasertib. 

Boehringer Ingelheim assigns to Oncoheroes the intellectual property of volasertib, with exclusive rights to R&D, sell and sublicense the compound. 

Oncoheroes is a Boston-based biotech company focused on the development of innovative medicines to treat cancer in children and adolescents. The company was co-founded in 2018 by Ricardo Garcia and Cesare Spadoni, two parents touched by childhood cancer and determined to change the outlook for these young patients.

“This is probably the first example of an investigational compound being specifically repurposed to investigate it as a treatment for a form of childhood cancer”, jointly stated Garcia and Spadoni.

More information

Sign up to Oncoheroes launching webinar!

Ricardo Garcia (CEO) and Cesare Spadoni (COO) will be presenting Oncoheroes and answering audience questions during a launching webinar on October 15, 2019.

Whether you have been touched by childhood cancer, or are a cancer foundation, a cancer researcher, an industry professional or a life science investor, and want to boost new therapies for young cancer patients, join this informative session to know more about what they do and how you can get involved.

Photo: Ricardo Garcia, co-founder and CEO of Oncohereos at the BIO Convention 2019.